Benzinga | Nov 5, 2020 09:48AM EST

Piper Sandler Maintains Overweight on Mirati Therapeutics, Raises Price Target to $260

Piper Sandler maintains Mirati Therapeutics (NASDAQ:MRTX) with a Overweight and raises the price target from $210 to $260.